Clinical trials
HIV-1 clinical trials
Below are recruiting hiv-1 clinical trials, each written for real people, not researchers. We’re tracking 78 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06967753RecruitingPhase 4
Switching to a two-drug HIV regimen for transgender women
This trial tests if switching to a two-drug combination of dolutegravir and lamivudine is safe and effective for transgender women who already have undetectable HIV levels on a three-drug regimen. It aims to simplify treatment and reduce side effects.
Buenos Aires, Buenos Aires F.D.Ages 18 years+ - NCT07392372RecruitingPhase 1
Testing the safety of BNT351 in people with and without HIV
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
Chicago, IllinoisAges 18–65 - NCT04883255RecruitingEarly Phase 1
Study cannabis effects on brain function in adults with HIV
This early-phase study looks at how cannabis (and the body’s cannabinoid system) may affect thinking and brain-related measures in people with HIV. You may be asked to avoid cannabis and complete several brain and health assessments to see how these factors relate.
San Diego, CaliforniaAges 18–65 - NCT06554717RecruitingPhase 2
Tesamorelin and exercise for physical function in HIV
This study tests whether adding tesamorelin to an exercise program helps older adults with HIV improve their physical function and reduce belly fat. It is designed for people who are mostly sedentary and show early signs of frailty.
Aurora, ColoradoAges 50–80 - NCT07186244Recruiting
HIV Prevention Study for People Starting or Taking PrEP
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
Chieti, AbruzzoAges 18 years+ - NCT06928090Enrolling by invitation
HIV trial testing two-med combo for first-time treatment
This trial studies a two-drug pill (DTG/3TC) for people who have never taken HIV medication before. It aims to see if this simpler treatment is effective and safe for controlling HIV-1.
DaejeonAges 19 years+ - NCT06337032RecruitingPhase 4
Continued access to HIV treatment for children and teens
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
Buenos AiresAges 1 month+ - NCT07202546RecruitingPhase 2
New oral HIV drug trial for people new to treatment
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
Bakersfield, CaliforniaAges 18 years+ - NCT04174755Recruiting
Semaglutide for weight loss in adults with HIV
This trial studies whether semaglutide (a diabetes-type weight-loss injection) helps adults with HIV lose weight. It also checks that it’s safe for people whose HIV is well controlled on regular treatment.
Dublin, DublinAges 18 years+ - NCT07342491RecruitingPhase 1
Testing dasatinib to shrink HIV reservoir
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
Chicago, IllinoisAges 18 years+ - NCT00039689Recruiting
Blood collection study for newly diagnosed HIV research
This research study collects blood cells from people recently diagnosed with HIV who haven't started HIV medicines yet. Researchers use these samples to understand how HIV affects the immune system and develop better treatments.
Bethesda, MarylandAges 18–120 - NCT05668026RecruitingPhase 1/Phase 2
Venetoclax to shrink HIV reservoir in people on stable ART
This Phase 1/2 study tests whether venetoclax can help reduce the “HIV reservoir,” which is a hidden group of HIV-infected cells, while you stay on your usual HIV treatment. It also looks at whether the drug helps these infected cells die off in a controlled, safe way.
AarhusAges 18–65 - NCT06648629Recruiting
Counseling to help HIV patients who drink too much
This study tests a counseling approach called Acceptance and Commitment Therapy (ACT) to help people living with HIV who drink at unhealthy levels reduce their drinking. If you're on HIV treatment and drink more than recommended, this program may help you build healthier habits.
Syracuse, New YorkAges 18 years+ - NCT00537966Recruiting
Study of new HIV infections in the Zurich area
This study enrolls people whose HIV infection is very recent or newly diagnosed (within the last few months). The researchers want to better understand early stages of HIV to improve how doctors identify and track new infections.
ZurichAges 18 years+ - NCT07044297RecruitingPhase 3
A study of a new long-acting shot to prevent HIV
This study tests an investigational long-acting shot (MK-8527) to prevent HIV. It is for HIV-negative people who are at higher risk through anal sex without condoms, and who have not used other long-acting HIV prevention before.
Birmingham, AlabamaAges 16 years+ - NCT07071623RecruitingPhase 3
A study of an experimental drug to prevent HIV
This trial tests a new medication called MK-8527 to see if it can prevent HIV-1 infection in women who are at risk. If you are a cisgender woman, HIV-negative, and sexually active, this study could be an option for you.
Homabay County, Homa Bay CountyAges 16–30 - NCT05419024RecruitingPhase 2
Imaging and biopsy during a planned HIV treatment pause
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
Bethesda, MarylandAges 18–100 - NCT00767312Enrolling by invitation
Study how HIV multiplies during HIV drug treatment
This study looks at how HIV continues to multiply (or stays suppressed) while you are taking antiretroviral therapy, using blood samples. It may help researchers better understand what HIV is doing during treatment and why some people experience changes like viral rebound.
Bethesda, MarylandAges 18–99 - NCT06890988Recruiting
Dental team study to help end HIV epidemic
This trial tests if training dental teams (dentists, hygienists, assistants, navigators) can help end the HIV epidemic by offering HIV testing and prevention in dental visits. You may be able to join if you work in a dental practice that is part of this study.
New York, New YorkAges 18 years+ - NCT06907056RecruitingPhase 4
A study on a simpler HIV medication combination
This study tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug regimen in men whose HIV is already well-controlled. If effective, this could mean taking fewer medications.
Mexico City, Mexico CityAges 18–70 - NCT07481175RecruitingPhase 1
Testing a drug to reduce hidden HIV early after treatment start
This trial tests whether adding venetoclax, a drug that helps infected cells die, at the start of HIV treatment can lower the amount of hidden virus that stays in the body. It may help reduce the HIV reservoir.
AarhusAges 18–70 - NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
San Francisco, CaliforniaAges 18 years+ - NCT07725042Recruiting
HIV infection study in Hong Kong for newly diagnosed adults
This study looks at people newly diagnosed with HIV in Hong Kong. It aims to understand patterns of infection to improve care.
North PointAges 18 years+ - NCT07293559Recruiting
Understanding infant feeding choices in women with HIV
This study looks at how women with HIV decide whether to breastfeed, and what support they get from healthcare providers and family. It aims to learn about their experiences and needs.
Los Angeles, CaliforniaAges Any age
Hear when a new HIV-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv-1?
- Yes. Clin2 currently lists 78 recruiting hiv-1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv-1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv-1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.